Program
picankibart
Its studies are mostly in Psoriasis · Arthritis, Psoriatic, led by Innovent Biologics.
Drug pagePicankibart: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 22 open or running | phase 3since Apr 18, 2025 | Apr 18, 2025 | Dec 31, 2029phase 3 · NCT07295509 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 19, 2023Named picankibartINNProposed as its International Nonproprietary Name in WHO's List 128
- Apr 18, 2025First study: phase 3 study in Plaque PsoriasisFirst studyNCT06945107 · 308 enrolled · China
- Nov 24, 2025Phase 3 study in Arthritis, PsoriaticNCT07295509 · 222 planned · China
Ahead
- Dec 31, 2029Primary completion: phase 3 study in Arthritis, PsoriaticNCT07295509
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07295509Arthritis, Psoriatic · China | 3 | Recruiting | Dec 31, 2029 | 222 |
| NCT06945107Plaque Psoriasis · China | 3 | Active, not recruiting | Jun 7, 2026 | 308 |
How it is read
Names in the registry
- “Picankibart”, 2 entries
Conditions, from the studies’ own filings
- Psoriasis, 1 study
- Arthritis, Psoriatic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.